Test Details - Acute Myelogenous Leukemia (AML) FISH Panel

Acute Myeloid Leukemia (AML) is a type of blood cancer that develops when the bone marrow produces abnormal and immature white blood cells that do not function properly. AML is a serious condition that requires prompt diagnosis and treatment. AML is diagnosed through a series of tests that comprise the AML panel, including a FISH analysis for the MLL gene. In this blog post, we will discuss the AML panel with MLL by FISH and its role in the diagnosis and treatment of AML.

The AML panel is a collection of laboratory tests that help to diagnose and classify AML. These tests typically include a complete blood count (CBC), bone marrow aspiration and biopsy, and genetic tests. The genetic tests aim to identify specific markers and mutations in the blood and bone marrow that indicate the presence and severity of AML.

One of the genetic tests used in the AML panel test is the FISH analysis for the MLL gene. The MLL gene is responsible for encoding proteins that regulate gene expression and cell differentiation. Mutations in the MLL gene are associated with poor prognosis and a higher risk of relapse in AML. The FISH analysis is a laboratory test that detects the location and quantity of the MLL gene in the nucleus of the cell using fluorescent probes.

The FISH analysis for MLL is particularly useful in cases where traditional cytogenetic testing fails to detect chromosomal abnormalities. It can detect subtle genetic mutations and rearrangements that are not visible under a microscope. The FISH analysis is also useful in identifying AML subtypes that have a specific genetic abnormality involving the MLL gene.

To perform the FISH analysis, a sample of bone marrow or blood is taken and labeled with fluorescent probes that bind to the MLL gene. The labeled sample is then viewed under a fluorescence microscope to detect the location and number of MLL genes in the cell. The results of the FISH analysis are reported as a percentage of cells that have the mutation. A higher percentage of cells with MLL mutations indicates a poorer prognosis and a higher risk of relapse.

The FISH analysis for MLL is often used in conjunction with other genetic tests, such as PCR and karyotyping, to provide a comprehensive diagnosis of AML. Together, these tests provide crucial information that guides treatment decisions and helps predict the patient's response to therapy. For example, patients with MLL mutations may require more intensive chemotherapy and closer monitoring due to their higher risk of relapse.

In summary, the AML panel with MLL by FISH is a comprehensive test that provides crucial information for the diagnosis and classification of AML. The FISH analysis for MLL is a powerful tool that can detect subtle genetic mutations that are not visible through traditional cytogenetic testing. The results of the FISH analysis for MLL are essential in determining the prognosis and guiding treatment decisions for patients with AML. If you have any concerns about AML or have been diagnosed with AML, speak with your healthcare provider to learn more about the AML panel and FISH analysis for MLL. Early diagnosis and treatment can significantly improve the prognosis and quality of life for patients with AML.